Compared to Estimates, Dentsply (XRAY) Q3 Earnings: A Look at Key Metrics

Dentsply (XRAY) reported Q3 2025 revenue of $904 million, a 4.9% year-over-year decline, which marginally surpassed consensus estimates by 0.27%. However, the company's EPS of $0.37 missed analyst expectations by 17.78% and was down from $0.50 a year prior. Segment performance was mixed, with strong revenue growth in Europe (+10.1%) and Wellspect Healthcare (+15.3%) partially offsetting a significant 22.2% decline in U.S. revenues and a 14.9% drop in Orthodontic and Implant Solutions sales. Despite the mixed financial results, Dentsply shares have outperformed the S&P 500 over the past month, returning +1.9%.

Analysis

Dentsply (XRAY) reported Q3 2025 revenue of $904 million, marking a 4.9% year-over-year decline, yet marginally surpassing the Zacks Consensus Estimate of $901.59 million by 0.27%. Conversely, the company's diluted EPS of $0.37 significantly missed analyst expectations of $0.45 by 17.78%, representing a notable decrease from $0.50 in the prior year. This mixed performance, characterized by a top-line beat but a bottom-line miss, contributes to a moderately negative sentiment for the quarter.

Regional revenue performance exhibited significant divergence, with U.S. revenues declining sharply by 22.2% year-over-year to $291 million, substantially underperforming estimates. In contrast, European revenues demonstrated robust growth of 10.1% to $382 million, exceeding analyst projections. Product segment sales also varied, with Wellspect Healthcare growing 15.3% to $83 million, while Orthodontic and Implant Solutions experienced a 14.9% decline to $205 million.

Adjusted Operating Income also presented a mixed picture, as Connected Technology Solutions missed estimates ($10 million vs. $19.2 million) and Essential Dental Solutions fell short ($116 million vs. $127.61 million). However, Wellspect Healthcare ($28 million vs. $24 million) and Orthodontic and Implant Solutions ($22 million vs. $15.66 million) operating income exceeded expectations, indicating some operational efficiencies in specific areas. Despite the overall negative earnings surprise, XRAY shares have outperformed the S&P 500 over the past month, returning +1.9% against the index's +1.3%, suggesting some resilience or prior low expectations.

Key Decisions for Investors

• Investors should closely monitor the persistent revenue weakness in the U.S. and Orthodontic and Implant Solutions segments, as these represent significant headwinds.
• The substantial EPS miss, despite a slight revenue beat, warrants caution regarding profitability and operational efficiency, particularly in Connected Technology Solutions and Essential Dental Solutions.
• Further analysis into the drivers of European and Wellspect Healthcare strength is advisable to assess their sustainability and potential to offset weaker areas.
• Consider the stock's current Zacks Rank #3 (Hold) and its recent outperformance against the S&P 500, which may indicate that some negative factors are already priced in or that positive segment growth is providing support.